Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial

被引:6
|
作者
Blom, Kerstin [1 ,2 ]
Forsell, Erik [1 ,2 ]
Hellberg, Monica [2 ]
Svanborg, Cecilia [1 ,2 ]
Jernelov, Susanna [1 ,2 ,3 ]
Kaldo, Viktor [1 ,2 ,4 ]
机构
[1] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden
[2] Stockholm Hlth Care Serv, Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Div Psychol, Stockholm, Sweden
[4] Linnaeus Univ, Fac Hlth & Life Sci, Dept Psychol, Vaxjo, Sweden
关键词
Insomnia; Depression; Comorbidity; Psychological treatment; Randomized controlled trial; COGNITIVE-BEHAVIORAL THERAPY; SLEEP RESTRICTION THERAPY; SELF-HELP; DSM-IV; MAJOR DEPRESSION; SOCIAL ANXIETY; FOLLOW-UP; CBT-I; METAANALYSIS; PHARMACOTHERAPY;
D O I
10.1159/000536063
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: Insomnia and depression are highly prevalent disorders and commonly occur together. Cognitive behavioral therapy for insomnia, CBT-I, has been shown to be effective in treating insomnia and also comorbid depression. However, it is unclear whether effects of CBT-I on depression are specific or nonspecific. Also, depressive symptoms often remain too high after CBT-I, indicating a need for improved treatments. The objective was to determine whether combining CBT-I with CBT for depression, without increasing treatment length, reduces both insomnia and depression more than CBT for depression with a placebo insomnia intervention. Methods: A 12-week double-blind randomized controlled trial with a 6-month follow-up in a psychiatric setting using therapist-guided internet-delivered treatments was conducted. Patients (N = 126) were diagnosed with insomnia disorder and major depression by physicians. Primary outcome measures were as follows: self-rating scales Insomnia Severity Index (ISI) and Montgomery-angstrom sberg Depression Rating Scale (MADRS-S). Results: The combined treatment showed specific effects on insomnia severity over the control treatment (p = 0.007) but was not more effective in reducing depression severity. Within-group effects (Cohen's d) at post and at 6 months were as follows: ISI 1.40 and 1.42 (combined treatment), 0.95 and 1.00 (control); MADRS-S 0.97 and 1.12 (combined), 0.88 and 0.89 (control). Conclusions: CBT-I shows large specific effects on insomnia severity and is superior to control in this regard. Both treatments had similar effects on depression severity, i.e., combining CBT-I with CBT for depression did not enhance outcomes on depression compared to control. We suggest CBT-I should always be offered to patients with insomnia and depression comorbidity, possibly as the first-hand choice. Combining it with a psychological treatment for depression could be too burdening and may not be beneficial.
引用
收藏
页码:100 / 113
页数:14
相关论文
共 50 条
  • [31] Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression
    Silvers, KM
    Woolley, CC
    Hamilton, FC
    Watts, PM
    Watson, RA
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2005, 72 (03): : 211 - 218
  • [32] Transcranial magnetic stimulation in the treatment of depression - A double-blind, placebo-controlled trial
    Fitzgerald, PB
    Brown, TL
    Marston, NAU
    Daskalakis, ZJ
    de Castella, A
    Kulkarni, J
    ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (10) : 1002 - 1008
  • [33] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ESZOPICLONE FOR THE TREATMENT OF INSOMNIA IN PATIENTS WITH CHRONIC LOW BACK PAIN
    Krystal, A. D.
    Preud'homme, X. A.
    Goforth, H. W.
    SLEEP, 2012, 35 : A216 - A216
  • [34] A Randomized, Double-Blind, Placebo-Controlled Trial of Eszopiclone for the Treatment of Insomnia in Patients with Chronic Low Back Pain
    Goforth, Harold W.
    Preud'homme, Xavier A.
    Krystal, Andrew D.
    SLEEP, 2014, 37 (06) : 1053 - 1060
  • [35] Double-blind, placebo-controlled trial of pioglitazone for bipolar depression
    Aftab, Awais
    Kemp, David E.
    Ganocy, Stephen J.
    Schinagle, Martha
    Conroy, Carla
    Brownrigg, Brittany
    D'Arcangelo, Nicole
    Goto, Toyomi
    Woods, Nicole
    Serrano, Mary Beth
    Han, Huiqin
    Calabrese, Joseph R.
    Gao, Keming
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 245 : 957 - 964
  • [36] VIQUALINE IN RESISTANT DEPRESSION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FARAVELLI, C
    ALBANESI, G
    SESSAREGO, A
    NEUROPSYCHOBIOLOGY, 1988, 20 (02) : 78 - 81
  • [37] A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
    Miller, I.
    Lynggaard, C. D.
    Lophaven, S.
    Zachariae, C.
    Dufour, D. N.
    Jemec, G. B. E.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (02) : 391 - 398
  • [38] Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial
    Levin, Frances R.
    Mariani, John J.
    Brooks, Daniel J.
    Pavlicova, Martina
    Cheng, Wendy
    Nunes, Edward V.
    DRUG AND ALCOHOL DEPENDENCE, 2011, 116 (1-3) : 142 - 150
  • [39] Pilocarpine spray for the treatment of xerostomia: a randomized, double-blind, placebo-controlled trial
    Fragoso Motta, Ana Carolina
    Marques, Vanessa Tonetto
    Cabral, Fernanda Fortes
    dos Santos Polvora, Tabata Larissa
    de Macedo, Leandro Dorigan
    Alencar Ramos Inocenttini, Lara Maria
    Ferreira Duarte, Maira Peres
    Oliveira, Fabiola Reis
    Rocha, Eduardo Melani
    de Freitas, Osvaldo
    Tirapelli, Camila
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : S319 - S319
  • [40] Levetiracetam as an Adjunctive Treatment for Mania: A Double-Blind, Randomized, Placebo-Controlled Trial
    Keshavarzi, Amir
    Sharifi, Aziz
    Jahangard, Leila
    Soltanian, Alireza
    Bruehl, Annette Beatrix
    Ahmadpanah, Mohammad
    Brand, Serge
    NEUROPSYCHOBIOLOGY, 2022, 81 (03) : 192 - 203